In the ever-evolving world of biotechnology, the addition of an industry powerhouse can signal a seismic shift. Allterum Therapeutics, Inc., a Houston-based trailblazer in cancer research, has done just that by appointing the renowned Dr. Yan Moore, MD, MBA, as its new Chief Executive Officer. Armed with an impressive pedigree of innovation and leadership, Dr. Moore joins Allterum at a pivotal juncture, as the company prepares to launch a Phase I/II clinical trial of its lead asset, 4A10, a potentially groundbreaking treatment for Acute Lymphoblastic Leukemia (ALL) and other CD127-expressing cancers.

A Leader with a Proven Track Record

Dr. Moore’s résumé reads like a masterclass in biopharmaceutical excellence. Prior to joining Allterum, he served as Chief Medical Officer for OMEGA Therapeutics, a company known for pushing the boundaries of epigenomic mRNA medicines. At OMEGA, Dr. Moore led the charge in transitioning the company into clinical trials and managing an ambitious pipeline of therapeutics targeting cancer, regenerative medicine, obesity, and more. His previous roles as Senior Vice President and Global Head of Oncology at Ipsen Pharmaceuticals, as well as leadership positions at Sanofi, GlaxoSmithKline, and Bristol Myers-Squibb, have solidified his reputation as a visionary in oncology drug development.

With degrees from Tel Aviv University’s Sackler School of Medicine and Drexel University’s MBA program, as well as advanced management training at Harvard and London Business Schools, Dr. Moore embodies the fusion of scientific brilliance and strategic business acumen.

A Turning Point for Allterum

Allterum's lead asset, 4A10, has generated significant buzz in the oncology community for its best-in-class potential. This monoclonal antibody targets CD127, a receptor frequently overexpressed in ALL and other cancers, offering hope to patients battling life-threatening diseases. According to Dr. Atul Varadhachary, who is transitioning from CEO to Executive Chair, Dr. Moore’s leadership arrives at the perfect time.

“Yan Moore’s unparalleled expertise and the respect he commands in the oncology ecosystem worldwide perfectly complement the progress we’ve made with 4A10,” said Dr. Varadhachary. “As we prepare to enter the clinic, we are optimistic about 4A10’s ability to transform the treatment landscape for CD127-expressing cancers.”

The Vision Ahead

For Dr. Moore, the mission is personal. “Joining Allterum at this critical juncture is incredibly exciting,” he shared. “The early data on 4A10 is both impressive and promising, especially for a disease like Acute Lymphoblastic Leukemia, where the unmet medical need is still staggering. Beyond ALL, the potential to expand 4A10 into other hematological malignancies, solid tumors, and even autoimmune diseases is immense.”

Dr. Moore is also passionate about collaboration. “This isn’t just about advancing a drug—it’s about partnering with the medical community and patients to redefine what’s possible in cancer treatment,” he said.

Why Houston Matters

Allterum’s roots in Houston—a city known for its groundbreaking medical advancements and home to the world-renowned Texas Medical Center—further amplify the significance of this next phase. Houston has long been a hub for innovation, and Dr. Moore’s appointment underscores the city’s growing influence in the global biotech arena.

A Bold New Chapter

As Allterum Therapeutics embarks on this exciting chapter under Dr. Moore’s leadership, the stakes are high, but so is the promise of transformative change. For the patients and families battling ALL and other CD127-expressing cancers, hope is no longer a distant dream—it’s on the horizon.